default author photo

Hidetoshi Hayashi

Kindai University

SCHOLARLY PAPERS

4

DOWNLOADS

106

TOTAL CITATIONS

0

Scholarly Papers (4)

Actions:
Email selected abstracts
1.

A Phase II Study (WJOG12819L) to Assess the Efficacy of Osimertinib in Patients with EGFR Mutation-Positive NSCLC in Whom Systemic Disease (T790M-Negative) Progressed after Treatment with First- Or Second-Generation EGFR TKIS and Platinum-Based Chemotherapy

Number of pages: 19 Posted: 04 Jan 2023
Masayuki Takeda, Mototsugu Shimokawa, Atsushi Nakamura, Kaname Nosaki, Yasutaka Watanabe, Terufumi Kato, Daisuke Hayakawa, Hiroshi Tanaka, Toshiaki Takahashi, Masahide Oki, Motoko Tachihara, Daichi Fujimoto, Hidetoshi Hayashi, Kakuhiro Yamaguchi, Shoichiro Yamamoto, Eiji Iwama, Koichi Azuma, Kazuo Hasegawa, Nobuyuki Yamamoto and Kazuhiko Nakagawa
Kindai University, Yamaguchi University, Sendai Kousei Hospital, National Cancer Center Hospital East, Saitama Cancer Center, Kanagawa Cancer Center, Juntendo University - Juntendo University Hospital, Niigata Cancer Center Hospital, Shizuoka Cancer Center, National Hospital Organization Nagoya Medical Center, Kobe University, Wakayama Medical University, Kindai University, Hiroshima University - Hiroshima University Hospital, Ehime University Graduate School of Medicine, Kyushu University - Kyushu University Hospital, Kurume University - Department of Internal Medicine, Japan Lung Cancer Alliance, Wakayama Medical University - Department of Pulmonary Medicine and Medical Oncology and Kindai University
Downloads 42 (1,157,785)

Abstract:

Loading...

lung cancer, EGFR, T790-negative, Osimertinib, Patient-initiated clinical trial

2.

Multicenter real-world data on first-line chemoimmunotherapy in patients with advanced non-small cell lung cancer and performance status 2: WJOG18424L

Number of pages: 45 Posted: 01 Oct 2025
Shunichi Kataoka, Takehito Shukuya, Taichi Miyawaki, Hiroshi Ohtsu, Daichi Fujimoto, Hidetoshi Hayashi, Yukihiro Toi, Toshihide Yokoyama, Terufumi Kato, Teppei Yamaguchi, Kaoru Tanaka, Satoru Miura, Motohiro Tamiya, Motoko Tachihara, Kohei Otsubo, Yuki Sato, Satoshi Ikeda, Shinya Sakata, Takeshi Masuda, Shinnosuke Takemoto, Nobuyuki Yamamoto, Isamu Okamoto and Kazuhisa Takahashi
affiliation not provided to SSRN, Juntendo University, Shizuoka Cancer Center, Juntendo University, Wakayama Medical University, Kindai University, Sendai Kousei Hospital, Kurashiki Central Hospital - Department of Respiratory Medicine, Kanagawa Cancer Center, affiliation not provided to SSRN, Kindai University, Niigata Cancer Center Hospital, Osaka International Cancer Institute, Kobe University, Kyushu University - Kyushu University Hospital, Kobe City Medical Center General Hospital, Kanagawa Cardiovascular and Respiratory Center, Kumamoto University - Kumamoto University Hospital, Hiroshima University - Hiroshima University Hospital, Nagasaki University, Wakayama Medical University - Department of Pulmonary Medicine and Medical Oncology, Kyushu University - Kyushu University Hospital and Juntendo University - Department of Respiratory Medicine
Downloads 29 (1,332,057)

Abstract:

Loading...

Non-small cell lung cancer, Performance status 2, Immune checkpoint inhibitors, Real-world evidence, First-line therapy

3.

The TIGOS Trial: A Randomized, Double-Blind, Phase III Trial of Atigotatug and Nivolumab Fixed-Dose Combination With Chemotherapy Versus Atezolizumab With Chemotherapy as First-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer

Number of pages: 30 Posted: 24 Nov 2025
Neal E. Ready, Luis Paz Ares, Kenneth O'Byrne, Melissa Johnson, Martin Reck, Nicolas Girard, Hidetoshi Hayashi, Caicun Zhou, Vishwanath Suresh Gharpure, Radhika Pisupati and Misena Pacius
Duke University - Duke Cancer Institute, University Hospital 12 de Octubre, Queensland University of Technology, Sarah Cannon Research Institute, German Centre for Lung Research - Lungen Clinic Grosshansdorf, PSL Research University - Institut Curie, Kindai University, Tongji University - Department of Medical Oncology, Bristol Myers Squibb, Bristol Myers Squibb and Bristol Myers Squibb
Downloads 24 (1,399,036)

Abstract:

Loading...

Nivolumab, atigotatug, extensive-stage small cell lung cancer, innate immune inducer, Fuc-GM1

4.

Efficacy of Second-Line Therapies for SMARCA4-Mutated NSCLC Based on Analysis of a Nationwide Comprehensive Genomic Profiling Database

Number of pages: 19 Posted: 28 Jan 2026
Daiki Murata, Takayuki Takahama, Hidetoshi Hayashi and Sneak Peek Administrator
Kindai University, Kindai University, Kindai University and Independent
Downloads 11 (1,534,404)

Abstract:

Loading...

C-CAT database, Comprehensive genomic profiling (CGP), docetaxel, Ramucirumab, Smarca4, STK11